{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:11:08Z","timestamp":1790665868579,"version":"4.1.0"},"reference-count":40,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Direction G\u00e9n\u00e9rale de l'Armement","award":["2010.94.092"],"award-info":[{"award-number":["2010.94.092"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Anthrax is an acute disease caused by the bacterium Bacillus anthracis, and is a potential biowarfare\/bioterrorist agent. Its pulmonary form, caused by inhalation of the spores, is highly lethal and is mainly related to injury caused by the toxins secretion. Antibodies neutralizing the toxins of B. anthracis are regarded as promising therapeutic drugs, and two are already approved by the Federal Drug Administration. We developed a recombinant human-like humanized antibody, 35PA83 6.20, that binds the protective antigen and that neutralized anthrax toxins in-vivo in White New Zealand rabbits infected with the lethal 9602 strain by intranasal route. Considering these promising results, the preclinical and clinical phase one development was funded and a program was started. Unfortunately, after 5 years, the preclinical development was cancelled due to industrial and scientific issues. This shutdown underlined the difficulty particularly, but not only, for an academic laboratory to proceed to clinical development, despite the drug candidate being promising. Here, we review our strategy and some preliminary results, and we discuss the issues that led to the no-go decision of the pre-clinical development of 35PA83 6.20 mAb. Our review provides general information to the laboratories planning a (pre-)clinical development.<\/jats:p>","DOI":"10.3390\/toxins14030172","type":"journal-article","created":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T20:49:03Z","timestamp":1645994943000},"page":"172","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Antibodies against Anthrax Toxins: A Long Way from Benchlab to the Bedside"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1759-7256","authenticated-orcid":false,"given":"Arnaud","family":"Avril","sequence":"first","affiliation":[{"name":"D\u00e9partement Microbiologie et Maladies Infectieuses, Institut de Recherche Biom\u00e9dicale des Arm\u00e9es, 91220 Br\u00e9tigny-sur-Orge, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4542-2421","authenticated-orcid":false,"given":"Jean-Nicolas","family":"Tournier","sequence":"additional","affiliation":[{"name":"D\u00e9partement Microbiologie et Maladies Infectieuses, Institut de Recherche Biom\u00e9dicale des Arm\u00e9es, 91220 Br\u00e9tigny-sur-Orge, France"},{"name":"Ecole du Val-de-Gr\u00e2ce, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Paucod","sequence":"additional","affiliation":[{"name":"D\u00e9partement Microbiologie et Maladies Infectieuses, Institut de Recherche Biom\u00e9dicale des Arm\u00e9es, 91220 Br\u00e9tigny-sur-Orge, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Fournes","sequence":"additional","affiliation":[{"name":"Laboratoire Fran\u00e7ais du Fractionnement et des Biotechnologies, 91940 Les Ulis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Thullier","sequence":"additional","affiliation":[{"name":"D\u00e9partement Microbiologie et Maladies Infectieuses, Institut de Recherche Biom\u00e9dicale des Arm\u00e9es, 91220 Br\u00e9tigny-sur-Orge, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4312-1032","authenticated-orcid":false,"given":"Thibaut","family":"Pelat","sequence":"additional","affiliation":[{"name":"D\u00e9partement Microbiologie et Maladies Infectieuses, Institut de Recherche Biom\u00e9dicale des Arm\u00e9es, 91220 Br\u00e9tigny-sur-Orge, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Friebe, S., van der Goot, F.G., and B\u00fcrgi, J. (2016). The Ins and Outs of Anthrax Toxin. Toxins, 8.","DOI":"10.3390\/toxins8030069"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.3389\/fmicb.2015.01122","article-title":"Crossing of the epithelial barriers by Bacillus anthracis: The Known and the Unknown","volume":"6","author":"Goossens","year":"2015","journal-title":"Front. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7589","DOI":"10.1073\/pnas.0509551103","article-title":"Sverdlovsk revisited: Modeling human inhalation anthrax","volume":"103","author":"Wilkening","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3201\/eid0810.020353","article-title":"Investigation of bioterrorism-related anthrax, United States, 2001: Epidemiologic findings","volume":"8","author":"Jernigan","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Thouret, J.-M., Rogeaux, O., Beaudouin, E., Levast, M., Ramisse, V., Biot, F.V., Valade, E., Thibault, F., Gorg\u00e9, O., and Tournier, J.-N. (2020). Case Report of an Injectional Anthrax in France, 2012. Microorganisms, 8.","DOI":"10.3390\/microorganisms8070985"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1017\/dmp.2018.113","article-title":"Medical Spending for the 2001 Anthrax Letter Attacks","volume":"13","author":"Zacchia","year":"2019","journal-title":"Disaster Med. Public Health Prep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3390\/toxins3111433","article-title":"Antibodies against anthrax: Mechanisms of action and clinical applications","volume":"3","author":"Froude","year":"2011","journal-title":"Toxins"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3201\/eid2301.160608","article-title":"Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009\u20132010","volume":"23","author":"Cui","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1128\/AAC.00546-16","article-title":"Revisiting the Concept of Targeting Only Bacillus anthracis Toxins as a Treatment for Anthrax","volume":"60","author":"Glinert","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/QCO.0000000000000446","article-title":"Does anthrax antitoxin therapy have a role in the treatment of inhalational anthrax?","volume":"31","author":"Vietri","year":"2018","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Xu, W., Ohanjanian, L., Sun, J., Cui, X., Suffredini, D., Li, Y., Welsh, J., and Eichacker, P.Q. (2017). A systematic review and meta-analysis of preclinical trials testing anti-toxin therapies for B. anthracis infection: A need for more robust study designs and results. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0189239"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1128\/AAC.01528-06","article-title":"High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation","volume":"51","author":"Pelat","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-1-4939-7447-4_5","article-title":"Thibaut construction of macaque immune-libraries","volume":"Volume 1701","author":"Hust","year":"2018","journal-title":"Phage Display"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2174\/15701638113109990030","article-title":"Isolation of antibodies from non-human primates for clinical use","volume":"11","author":"Avril","year":"2014","journal-title":"Curr. Drug Discov. Technol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Avril, A., Miethe, S., Popoff, M.R., Mazuet, C., Chahboun, S., Rasetti-Escargueil, C., Sesardic, D., Thullier, P., Hust, M., and Pelat, T. (2015). Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain. BMC Biotechnol., 15.","DOI":"10.1186\/s12896-015-0206-0"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"R\u00fclker, T., Vo\u00df, L., Thullier, P., O\u2019 Brien, L.M., Pelat, T., Perkins, S.D., Langermann, C., Schirrmann, T., D\u00fcbel, S., and Marschall, H.-J. (2012). Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0037242"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4161\/mabs.2.5.12545","article-title":"A comparison of human and macaque (Macaca mulatta) immunoglobulin germline V regions and its implications for antibody engineering","volume":"2","author":"Thullier","year":"2010","journal-title":"MAbs"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Rasetti-Escargueil, C., Avril, A., Miethe, S., Mazuet, C., Derman, Y., Selby, K., Thullier, P., Pelat, T., Urbain, R., and Fontayne, A. (2017). The European AntibotABE Framework Program and Its Update: Development of Innovative Botulinum Antibodies. Toxins, 9.","DOI":"10.3390\/toxins9100309"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Pelat, T., Hust, M., Hale, M., Lefranc, M.-P., D\u00fcbel, S., and Thullier, P. (2009). Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol., 9.","DOI":"10.1186\/1472-6750-9-60"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jconrel.2016.05.018","article-title":"Development of a drug delivery system for efficient alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary intoxication to ricin","volume":"234","author":"Respaud","year":"2016","journal-title":"J. Control Release"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Orsini Delgado, M.L., Avril, A., Prigent, J., Dano, J., Rouaix, A., Worbs, S., Dorner, B.G., Rougeaux, C., Becher, F., and Fenaille, F. (2021). Ricin Antibodies\u2019 Neutralizing Capacity against Different Ricin Isoforms and Cultivars. Toxins, 13.","DOI":"10.3390\/toxins13020100"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1080\/19420862.2017.1299848","article-title":"Generation and characterization of protective antibodies to Marburg virus","volume":"9","author":"Froude","year":"2017","journal-title":"MAbs"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Froude, J.W., Herbert, A.S., Pelat, T., Miethe, S., Zak, S.E., Brannan, J.M., Bakken, R.R., Steiner, A.R., Yin, G., and Hallam, T.J. (2018). Post-Exposure Protection in Mice against Sudan Virus by a Two Antibody Cocktail. Viruses, 10.","DOI":"10.3390\/v10060286"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1128\/AAC.49.8.3414-3420.2005","article-title":"Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694","volume":"49","author":"Laffly","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Thullier, P., Avril, A., Mathieu, J., Behrens, C.K., Pellequer, J.-L., and Pelat, T. (2013). Mapping the epitopes of a neutralizing antibody fragment directed against the lethal factor of Bacillus anthracis and cross-reacting with the homologous edema factor. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0065855"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.jmb.2008.10.033","article-title":"Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering","volume":"384","author":"Pelat","year":"2008","journal-title":"J. Mol. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Kn\u00e4blein, D.J. (2013). Massive Mutagenesis\u00ae: The path to smarter genetic libraries. Modern Biopharmaceuticals, Wiley-VCH Verlag GmbH & Co., KGaA.","DOI":"10.1002\/9783527669417"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jmb.2008.03.045","article-title":"Improvement of an antibody neutralizing the anthrax toxin by simultaneous mutagenesis of its six hypervariable loops","volume":"378","author":"Laffly","year":"2008","journal-title":"J. Mol. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jmr.846","article-title":"Functional reconstruction and synthetic mimicry of a conformational epitope using CLIPS technology","volume":"20","author":"Timmerman","year":"2007","journal-title":"J. Mol. Recognit."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/nbt891","article-title":"Human antibodies from immunized donors are protective against anthrax toxin in vivo","volume":"21","author":"Wild","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1476-8518-2-5","article-title":"Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed","volume":"2","author":"Jiang","year":"2004","journal-title":"J. Immune Based Ther. Vaccines"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1128\/IAI.00712-06","article-title":"Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity","volume":"74","author":"Vitale","year":"2006","journal-title":"Infect. Immun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1086\/500148","article-title":"Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen","volume":"193","author":"Chen","year":"2006","journal-title":"J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3389\/fmicb.2015.01320","article-title":"Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration \u201cAnimal Rule\u201d","volume":"6","author":"Tsai","year":"2015","journal-title":"Front. Microbiol."},{"key":"ref_35","unstructured":"Agency, E.M. (2022, February 22). Assessment Report Obiltoxaximab SFL, 17\/09\/2020. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/obiltoxaximab-sfl-epar-public-assessment-report_en.pdf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa0810603","article-title":"Raxibacumab for the treatment of inhalational anthrax","volume":"361","author":"Migone","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s00253-020-10368-7","article-title":"Antibody glycosylation: Impact on antibody drug characteristics and quality control","volume":"104","author":"Wang","year":"2020","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S0140-6736(96)90901-0","article-title":"Fulminant meningitis due to Bacillus anthracis in 11-year-old girl during Ramadan","volume":"347","author":"Berthier","year":"1996","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1128\/IAI.00446-06","article-title":"Bacillus anthracis spores stimulate cytokine and chemokine innate immune responses in human alveolar macrophages through multiple mitogen-activated protein kinase pathways","volume":"74","author":"Chakrabarty","year":"2006","journal-title":"Infect. Immun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1128\/IAI.00575-07","article-title":"Noncapsulated toxinogenic Bacillus anthracis presents a specific growth and dissemination pattern in naive and protective antigen-immune mice","volume":"75","author":"Glomski","year":"2007","journal-title":"Infect. Immun."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/3\/172\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:27:14Z","timestamp":1760135234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/3\/172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["toxins14030172"],"URL":"https:\/\/doi.org\/10.3390\/toxins14030172","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,25]]}}}